一种双对应的分子粘剂连接氨酸乙烯转移酶到基因诱导的细胞死亡
Meredith N Nix1,2, Sai Gourisankar1, Roman C Sarott1
1Department of Chemical and Systems Biology, Stanford University, Stanford, CA, USA.
bioRxiv : the preprint server for biology
|April 1, 2025
概括
研究人员开发了新的近距离化学诱导剂 (KAT-TCIPs),以向扩散大B细胞淋巴瘤. 这些化合物通过重定向表观遗传修饰剂来激活细胞死亡基因,提供了一种新的精确表观遗传疗法方法.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 强大的癌细胞死亡对于预防免疫疗法等疗法复发至关重要.
- 扩散性大B细胞淋巴瘤 (DLBCL) 是最常见的非霍奇金淋巴瘤,需要针对性的治疗策略.
研究的目的:
- 提供结构和分子洞察力,用于DLBCL中使用化学诱导的近距离杀死特定细胞的新方法.
- 开发和表征KAT-TCIPs (临近的lysine acetyltransferase转录/表观遗传化学诱导剂) 用于向的癌症治疗.
主要方法:
- 开发KAT-TCIPs以重定向p300和CBP.
- 通过致癌驱动体BCL6.6抑制的编程细胞死亡基因的激活.
- 通过p300-BCL6复合物的晶体结构进行结构分析.
主要成果:
- 在急性治疗时,KAT-TCIPs重新编程表观基因组以启动细胞灭绝并抑制c-MYC.
- 晶体结构阐明了如何利用特定的蛋白质相互作用来产生强效和选择性的治疗效果.
- 已证明瘤原驱动器功能的合作作用可以激活细胞死亡.
结论:
- 这项研究为针对DLBCL的精密表观遗传疗法提供了基础.
- 开发的KAT-TCIPs提供了一种新的策略,通过操纵表观遗传调节器来诱导强大的癌细胞死亡.
- 为了获得治疗效益,利用致癌驱动因素是癌症治疗中一个有前途的途径.
相关概念视频
Covalently Linked Protein Regulators
6.7K
Proteins can undergo many types of post-translational modifications, often in response to changes in their environment. These modifications play an important role in the function and stability of these proteins. Covalently linked molecules include functional groups, such as methyl, acetyl, and phosphate groups, and also small proteins, such as ubiquitin. There are around 200 different types of covalent regulators that have been identified.
These groups modify specific amino acids in a protein....
These groups modify specific amino acids in a protein....
6.7K
The Intrinsic Apoptotic Pathway
5.7K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
5.7K
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Anaphase Promoting Complex
2.8K
The stepwise destruction of specific proteins is necessary for the progression and completion of the cell cycle. Such proteins are ubiquitinated by ubiquitin ligases and then subsequently destroyed by the proteasome. The SCF (Skp1/Cullin/F-box) and the anaphase-promoting complex (APC) are two important ubiquitin ligases involved in cell cycle progression. While SCF is active throughout the cell cycle, APC gets activated during metaphase to anaphase transition. Cdc20 or Cdh1 binds to APC and...
2.8K
Targeted Cancer Therapies
7.4K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.4K
Amplifying Signals via Enzymatic Cascade
8.2K
When a ligand binds to a cell-surface receptor, the receptor's intracellular domain changes shape, which may either activate its enzyme function or allow its binding to other molecules. The initial signal is amplified by most signal transduction pathways. This means that a single ligand molecule can activate multiple molecules of a downstream target. Proteins that relay a signal are most commonly phosphorylated at one or more sites, activating or inactivating the protein. Kinases catalyze...
8.2K


